Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler(University of Chicago), Richard M. Goldberg(Ontario Institute for Cancer Research), Joel Picus(Washington University in St. Louis), Mary F. Mulcahy(Northwestern University), Pankaj Bhargava(University of North Carolina at Chapel Hill), Federico Innocenti(AbbVie (United States)), Herbert I. Hurwitz(Duke Medical Center), Robert J. Mayer(Applied Natural Sciences), Donna Niedzwiecki(Duke University), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Deborah Schrag(Dana-Farber Brigham Cancer Center), Susan Sutherland(University of North Carolina at Chapel Hill), Donna Hollis(University of North Carolina at Chapel Hill), Timothy F. Wozniak(University of North Carolina at Chapel Hill), Richard L. Schilsky(American Society of Clinical Oncology)
Cited by 840
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k